Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 16 symbols : Lly save search
ReCode Therapeutics Appoints Angèle Maki, Ph.D., as Senior Vice President of Business Development
Published: 2021-08-16 (Crawled : 13:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
ev
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study
Published: 2021-08-16 (Crawled : 13:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.53%
H: 0.72%
C: 0.68%
therapy phase 3
FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps
Published: 2021-08-16 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
fda injection insulin fda approval
Insulet Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States
Published: 2021-08-16 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
PODD | $164.71 -0.93% -0.94% 590K
|
Health Technology
|
| O: 2.16%
H: 2.81%
C: 2.29%
fda clearance fda insulin clearance
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Published: 2021-08-16 (Crawled : 07:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
dermatitis phase 3 skin trial atopic dermatitis clearance
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2021-08-16 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.53%
H: 0.72%
C: 0.68%
treatment therapy phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.